Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nada Amllal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Abdelaziz Sefiani

    4 shared publications
  • Jaber Lyahyai

    Research Team in Genomics and Molecular Epidemiology of Genetic Diseases, Genopath Centre, Faculty of Medicine and Pharmacy of Rabat University Mohammed V of Rabat Rabat Morocco

    3 shared publications
  • Siham Chafai Elalaoui

    Research Team in Genomics and Molecular Epidemiology of Genetic Diseases, Genopath Centre, Faculty of Medicine and Pharmacy of Rabat University Mohammed V of Rabat Rabat Morocco

    3 shared publications
  • Abdelaziz Sefiani

    Department of Medical Genetics National Institute of Hygiene Rabat Morocco

    2 shared publications
  • Jaber Lyahyai

    Research Team in Genomics and Molecular Epidemiology of Genetic Diseases, Genopath Centre, Faculty of Medicine and Pharmacy of Rabat University Mohammed V Rabat Morocco

    2 shared publications
  • Siham Chafai Elalaoui

    Département de Génétique Médicale, Institut National d'Hygiène, Rabat, Morocco

    2 shared publications

Latest Publications

  • Clinical Exome Sequencing as a Key Diagnostic Tool: A Rare de novo TRIO Variant in Dizygotic Twins

    by Hicham Bouchahta, Maryem Sahli, Nada Amllal, Mouna Ouhenach, Laila Sbabou, Abdelaziz Sefiani

    Introduction: TRIO-associated neurodevelopmental disorders are rare genetic conditions caused by pathogenic variants in the TRIO gene, which plays a crucial role in neuronal development. Mutations in the TRIO gene are increasingly associated with autosomal dominant inheritance. However, de novo occurrences in dizygotic twins remain rare and poorly understood. Case Presentation: In this work, clinical exome sequencing (CES) was performed on dizygotic twin sisters who presented with neurodevelopmental delay, intellectual disability, behavioral issues, and microcephaly. Segregation analysis using conventional Sanger sequencing was conducted on the parents to assess the inheritance pattern. A pathogenic missense variant c.4283G>A (p.Arg1428Gln) in the GEFD1 domain of the TRIO gene was identified. This variant is known to reduce GEF activity toward Rac1, impacting neuronal signaling pathways. Segregation analysis did not detect the variant in the parents, and mosaicism remains a possibility that could not be fully ruled out due to the limitations of this technique. Despite the lack of a definitive molecular diagnosis in the parents, detailed genetic counseling was provided to the family. Conclusion: These findings highlight the diagnostic value of CES in rare neurodevelopmental disorders and suggest a plausible but unproven parental germline or early postzygotic mosaic event, while acknowledging alternative explanations.

  • Highlighting the different facets of SMC1A truncating variants: Two patients with novel SMC1A pathogenic variants

    by Nada Amllal, Jaber Lyahyai, Lamiae Afif, Yamna Kriouile, Abdelaziz Sefiani, Siham Chafai Elalaoui


  • Novel variant related to SATB2‐associated syndrome

    by Nada Benyahya, Nada Amllal, Siham Chafai Elalaoui, Mustapha El Alloussi, Abdelaziz Sefiani, Jaber Lyahyai

    Background: SATB2‐associated syndrome (SAS) also known as Glass syndrome is characterized by/intellectual disability and/or developmental delay coupled with absent or limited speech development. Other abnormalities can be noticed including craniofacial anomalies such as palatal and dental anomalies, behavioural problems and dysmorphic features. It is associated with pathogenic monoallelic variants of the SATB2 gene known to play a key role in brain, dental and jaw development. As phenotype could be unspecific and progressive, clinical diagnostic is difficult. Therefore, genetic testing is mandatory to confirm the disease. Herein, we report clinical and molecular data of a 13‐year‐old girl with psychomotor developmental delay and behavioural problems.Methods and results: Next‐generation sequencing detected the novel monoallelic frameshift variant SATB2(NM_001172509.2): c.1135del(p.Gln379Lysfs*34). Currently, this variant is classified as likely pathogenic according to the American College of Medical Genetics. Sanger sequencing was used to validate the presence of the detected variant in the patient and confirm de novo character of this latter.Conclusion: Through this work, we emphasize the value of next‐generation sequencing for a precise molecular diagnosis, an adapted clinical management of patients and an adequate genetic counselling of their families.

  • A series of four patients with Sotos syndrome harboring novel NSD1 mutations: clinical and molecular description

    by Nada Amllal, Maria Zerkaoui, Wafaa Jdioui, Siham Chafai Elalaoui, Abdelaziz Sefiani, Jaber Lyahyai

    Background Sotos syndrome is a rare and complex genetic disorder caused by haploinsufficiency of the NSD1 gene. This syndrome is characterized by rapid early childhood growth, distinct facial features, a learning disability, and multiple other developmental and behavioral challenges. Methods and results In this work, we describe four Moroccan patients with variable clinical presentations of Sotos syndrome, in whom we identified four novel NSD1 monoallelic pathogenic variants by conducting targeted Next Generation Sequencing. Genetic testing allowed us to provide a precise medical diagnosis to our patients and tailor interventions to each patient’s needs. Conclusions Being the first work describing a series of Moroccan patients with this syndrome, this case series contributes to the growing body of literature on Sotos syndrome and provides valuable insights into the clinical and molecular characteristics of this rare disorder.

  • Novel Splice Site Pathogenic Variant in STXBP1 Gene in a Child with Intellectual Disability, Epilepsy, and Autism Spectrum Disorder: A Case Report

    by Nada Amllal, Jaber Lyahyai, Siham Chafai Elalaoui, Youssef El Kadiri, Abdelaziz Sefiani

    Introduction: Pathogenic variants in the STXBP1 gene are associated to a large spectrum of severe early onset developmental and epileptic encephalopathies (OMIM #612164). They were also identified in various other neurodevelopmental disorders. This gene encodes for the syntaxin-binding protein 1, a member of the SEC-1 family of membrane-transport proteins that modulate the presynaptic vesicular fusion by interacting with soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs). However, the physiopathology of STXBP1 pathogenic variants is not yet fully understood. Case Presentation: Herein, we report a patient presenting intellectual disability, early onset seizures, and autism. Clinical exome sequencing identified a novel monoallelic splice pathogenic variant STXBP1(NM_001032221.6):c.38–2A>G. Discussion: Splice-site pathogenic variants in the STXBP1 gene are mostly associated with West syndrome, early onset epilepsy and encephalopathy, and Ohtahara syndrome. Our findings extend clinical and molecular spectrum of STXBP1 gene variants by reporting the first splice-site variant associated with autism along with early onset epilepsy and, and intellectual disability in a patient.


  • Open Access

    Identification of Two Novel ANKRD11 Mutations: Highlighting Incomplete Penetrance in KBG Syndrome

    by Nada Amllal, Siham Chafai Elalaoui, Maria Zerkaoui, Amal Chiguer, Lamia Afif, Amal Thimou Izgua, Abdelaziz Sefiani, Jaber Lyahyai

    Nada Amllal, Ph.D., Siham Chafai Elalaoui, M.D., Maria Zerkaoui, M.D., Amal Chiguer, M.D., Lamia Afif, M.D., Amal Thimou Izgua, M.D., Abdelaziz Sefiani, M.D., and Jaber Lyahyai, Ph.D.. Ann Lab Med 2024;44:110-7. https://doi.org/10.3343/alm.2024.44.1.110